U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07401199) titled 'Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)' on Feb. 03.
Brief Summary: Gastric cancer is a major global health challenge. Currently, a combination of chemotherapy and immunotherapy (PD-1 inhibitors) is frequently used before surgery to shrink tumors, a strategy known as neoadjuvant therapy. While this approach is effective for many patients, responses vary significantly, and there are currently no reliable tools to predict which patients will benefit the most before treatment begins.
The PRISM-GC study aims to develop and validate a novel Artificial Intelligence (AI) system to ad...